pacidamycin 1: structure given in first source; isolated from Streptomyces coeruleorubidus; has anti-Pseudomonas aeruginosa activity [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 3035918 |
| MeSH ID | M0166598 |
| Synonym |
|---|
| pacidamycin 1 |
| 2-[[[(6s)-2,6-diamino-3-[[(2s)-2-[[(2s)-2-aminopropanoyl]amino]-3-(3-hydroxyphenyl)propanoyl]-methylamino]-5-oxoheptanoyl]-[(e)-[5-(2,4-dioxopyrimidin-1-yl)-4-hydroxyoxolan-2-ylidene]methyl]carbamoyl]amino]-3-(1h-indol-3-yl)propanoic acid |
| 121264-05-9 |
| a 68567 |
| butanamide, n-(((1-carboxy-2-(1h-indol-3-yl)ethyl)amino)carbonyl)alanyl-n3-(n-alanyl-3-hydroxyphenylalanyl)-n-((5-(3,4-dihydro-2,4-dioxo-1(2h)-pyrimidinyl)dihydro-4-hydroxy-2(3h)-furanylidene)methyl)-n3-methyl-2,3-diamino- |
| a-68567 |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 3 (37.50) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (62.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.27) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 1 (12.50%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 7 (87.50%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||